Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Commercial services entities : Eli lilly and company save search
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -1.06%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.9%
H: 2.03%
C: 1.89%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -0.53%
H: 2.22%
C: -3.59%
ALT | $6.91 0.29% 0.29% 3.6M
|
Commercial Services
|
| O: 0.3%
H: 11.41%
C: 9.8%
medical program
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
Published: 2024-01-22 (Crawled : 22:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
MDGL | $212.33 -4.47% -4.68% 620K
|
Health Technology
|
| O: 1.29%
H: 0.35%
C: -3.04%
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: -0.48%
H: 7.69%
C: 1.44%
ALT | $6.91 0.29% 0.29% 3.6M
|
Commercial Services
|
| O: -0.8%
H: 6.02%
C: 0.6%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.46%
H: 3.04%
C: 2.67%
ETNB | $9.08 2.25% 2.2% 1M
|
Health Technology
|
| O: 1.19%
H: 0.63%
C: -0.72%
liver disease companies key growth market
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
Published: 2023-10-03 (Crawled : 10:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
ALXO M | $15.6 -0.89% -0.9% 480K
|
Commercial Services
|
| O: 68.19%
H: 2.84%
C: -7.17%
aspen-06 positive cancer treatment trial results
Diabetic Peripheral Neuropathy Market Growing at a CAGR of ~6% by 2032 | DelveInsight
Published: 2023-07-20 (Crawled : 21:00) - prnewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: 0.71%
H: 3.64%
C: 0.61%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.16%
H: 1.18%
C: 0.88%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.34%
H: 0.35%
C: -0.72%
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: 0.86%
H: 0.57%
C: -0.68%
APLT A | $4.4 -7.17% -7.73% 2.9M
|
Health Technology
|
| O: 1.46%
H: 6.12%
C: 2.88%
ALT | $6.91 0.29% 0.29% 3.6M
|
Commercial Services
|
| O: 1.57%
H: 0.0%
C: -2.79%
growing market diabetic
Nonalcoholic Steatohepatitis Market Evolving at a Rapid Pace, Predicts DelveInsight | Key Companies Active in the Domain - Madrigal, Intercept, AstraZeneca, Gilead, Pfizer, Alnylam, Eli Lilly and Company, Novo Nordisk
Published: 2023-04-24 (Crawled : 15:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -1.02%
H: 0.31%
C: -0.24%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.0%
H: 0.47%
C: -0.49%
VKTX | $63.38 -2.0% -2.04% 3M
|
Health Technology
|
| O: 0.99%
H: 2.87%
C: -0.42%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.22%
H: 0.0%
C: 0.0%
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 0.63%
H: 1.35%
C: 0.45%
MDGL | $212.33 -4.47% -4.68% 620K
|
Health Technology
|
| O: -0.33%
H: 1.28%
C: 1.12%
LPCN | $5.33 -2.02% -2.06% 11K
|
Health Technology
|
| O: -2.31%
H: 7.94%
C: 1.01%
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -3.64%
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 0.04%
H: 1.48%
C: -3.31%
GALT | $3.37 -0.3% -0.3% 210K
|
Health Technology
|
| O: 0.0%
H: 1.04%
C: -4.17%
CWBR | $0.9003 -11.88% 360
|
Health Technology
|
| O: -3.68%
H: 1.1%
C: -1.63%
ALT | $6.91 0.29% 0.29% 3.6M
|
Commercial Services
|
| O: -0.69%
H: 0.87%
C: -4.0%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.08%
H: 0.18%
C: -2.07%
ETNB | $9.08 2.25% 2.2% 1M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: -5.88%
companies active rapid market
Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements Exicure, Inc. an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting r...
Published: 2022-12-14 (Crawled : 12:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.1%
H: 2.9%
C: 1.25%
XCUR 4 | $0.5825 0.64% 0.64% 22K
|
Commercial Services
|
| O: 0.0%
H: 11.14%
C: 0.79%
collaboration
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer
Published: 2022-08-11 (Crawled : 16:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.18%
H: 1.46%
C: 0.05%
ALXO M | $15.6 -0.89% -0.9% 480K
|
Commercial Services
|
| O: 2.97%
H: 6.15%
C: -1.44%
trial cancer phase 2
Metastatic Castration-Sensitive Prostate Cancer Market to Reach Upto USD 5.5 billion by 2032 | DelveInsight
Published: 2022-06-20 (Crawled : 16:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
XCUR 4 | $0.5825 0.64% 0.64% 22K
|
Commercial Services
| Email alert
Add to watchlist
ADAP | $0.97 7.97% 7.38% 1.5M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
EVLO | $0.3165 -87.39% 710K
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
cancer market prostate cancer
ALX Oncology Announces Evorpacept Clinical Program Updates
Published: 2022-06-03 (Crawled : 12:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.25%
H: 0.0%
C: 0.0%
ALXO M | $15.6 -0.89% -0.9% 480K
|
Commercial Services
|
| O: 1.49%
H: 3.07%
C: 1.6%
program
Global Clinical Trials Market Research Report to 2026 - Featuring Accell Clinical Research, Clinipace and Icon PLC Among Others
Published: 2022-04-05 (Crawled : 13:00) - prnewswire.com
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: -0.89%
H: 1.51%
C: -0.1%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 0.57%
H: 1.02%
C: 0.31%
IQV | $228.09 0.41% 0.0% 760K
|
Health Services
|
| O: -0.39%
H: 1.68%
C: 0.34%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.1%
H: 1.41%
C: 0.26%
CRL | $226.78 -0.34% 0.0% 410K
|
Commercial Services
|
| O: 0.35%
H: 1.06%
C: 0.14%
SYNH | $42.98 0.0% 7.4M
|
Health Services
|
| O: -0.06%
H: 0.4%
C: -0.82%
ICLR | $288.32 -1.2% -1.21% 640K
|
Health Technology
|
| O: 0.07%
H: 0.52%
C: -0.43%
trials research report market
ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction CancerPhase 2/3 study initiated in collaboration with Eli Lilly and Company
Published: 2022-03-02 (Crawled : 18:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
ALXO M | $15.6 -0.89% -0.9% 480K
|
Commercial Services
|
| O: 0.0%
H: 4.13%
C: 3.97%
aspen-06 treatment phase 2 phase 2/3 collaboration cancer initiated
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022
Published: 2022-01-10 (Crawled : 12:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
ALXO M | $15.6 -0.89% -0.9% 480K
|
Commercial Services
|
| O: -0.46%
H: 2.63%
C: 1.7%
milestone
ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer
Published: 2021-06-10 (Crawled : 12:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.43%
H: 3.91%
C: 2.89%
ALXO M | $15.6 -0.89% -0.9% 480K
|
Commercial Services
|
| O: -0.43%
H: 3.82%
C: 2.26%
cancer agx148